From motion to molecules: exercise-triggered large EVs suppress oncogenic signaling in lung adenocarcinoma cells – an in vitro pilot study
4 affiliations
- 1Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Pécs, Pécs, Hungary
- 2Histology and Light Microscopy core facility at the Szentágothai Research Centre, University of Pécs, Pécs, Hungary
- 3Department of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary
- 4Faculty of Science, Institute of Sport Sciences and Physical Education, University of Pécs, Pécs, Hungary
Abstract
Background: Although regular physical activity is known to reduce cancer risk, the circulating molecular mechanisms responsible for these effects remain incompletely defined. Exercise alters the release and composition of extracellular vesicles (EVs), suggesting a role in systemic anti-tumor signaling. However, the contribution of large EVs (L-EVs) ─ a distinct and understudied EV subtype ─ to the regulation of lung adenocarcinoma cell behaviour has not been examined to date.
Methods: L-EVs were isolated from platelet-free plasma of healthy, regularly exercising older adults with over 25 years of training history (aged 61 ± 2 years), collected at rest (Pre) and after (Post) an acute endurance exercise bout. EV fractions were characterized via transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and antibody-based profiling. PC9 lung adenocarcinoma cells were incubated with plasma-derived L-EV–enriched fractions for 24 h. Cell viability and metabolic activity were evaluated using ATP-based luminescence and XTT assays following L-EV treatment. miRNA and gene expression changes were assessed using RT-qPCR with TaqMan arrays. Differentially expressed miRNAs (DEmiRs) and genes (DEGs) were analysed using Ingenuity Pathway Analysis (IPA) to evaluate regulatory networks and predict functional outcomes.
Results: Exercise significantly increased plasma nanoparticle concentration (mean increase of 5.05 × 10⁷ ± 9.99 × 10⁶ particles/mL; p < 0.001, Cohen’s d = 1.685). TEM and NTA confirmed successful isolation of L-EVs, with mode sizes of 136.1 ± 23.6 nm pre-exercise and 129.5 ± 17.7 nm post-exercise. In PC9 cells, both Pre- and Post-L-EVs reduced metabolic activity compared to control conditions, as demonstrated by ATP-based and XTT assays, indicating a functional impact on cell viability (p < 0.001). Transcriptomic analysis revealed distinct expression changes between conditions. Post-L-EVs downregulated oncogenic and immune evasion–associated genes (MAX, FASLG, and ELK1) while upregulating pro-apoptotic and cell cycle inhibitory genes (CASP9, FADD, and CDKN2B). Several DEmiRs, including miR-21-5p, miR-301b-3p, and miR-193a-3p, shifted in directions opposite to their known oncogenic patterns in NSCLC, suggesting a tumor-suppressive influence. IPA predicted enhanced apoptotic signaling and reduced metastatic potential following Post-L-EV treatment.
Conclusion: Exercise-conditioned plasma-derived enriched L-EVs modulate gene and miRNA expression in lung adenocarcinoma cells toward a tumor-suppressive profile. By attenuating oncogenic and immune-evasion signals while enhancing apoptotic and cell cycle–inhibitory pathways, Post-L-EVs offer preliminary mechanistic insight into the anti-cancer potential of physical activity. Their origin from older adults engaged in long-term exercise highlights the systemic benefits of sustained activity and the promise of L-EVs as biomarkers of exercise responsiveness.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12935-026-04429-6.
Related
- Hijacking Cellular S-Acylation with Molecular Assemblies Rewires Oncogenic Signaling
- UFSP2 constitutes a targetable vulnerability via deUFMylation-dependent activation of AKT oncogenic signaling
- N-WASP deficiency enhances oncogenic KRAS-mediated lung adenocarcinoma progression in mice
- BCAM-AKT2 fusion protein promotes unfolded protein response driven oncogenic signaling in SKOV3 epithelial ovarian cancer cell line
- Oncogenic modulation of MAPK signaling in leukemia via SPNS2-driven sphingolipid metabolism and membrane nanodomains remodeling
BibTeX
@article{adam2026from,
title = {{From motion to molecules: exercise-triggered large EVs suppress oncogenic signaling in lung adenocarcinoma cells – an in vitro pilot study}},
author = {Zoltan Adam and Kitti Garai and Abigel Sebok-Tornai and Marta Wilhelm and Krisztian Kvell},
journal = {Cancer Cell International},
year = {2026},
month = jul,
doi = {10.1186/s12935-026-04429-6},
url = {https://doi.org/10.1186/s12935-026-04429-6},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - From motion to molecules: exercise-triggered large EVs suppress oncogenic signaling in lung adenocarcinoma cells – an in vitro pilot study
AU - Zoltan Adam
AU - Kitti Garai
AU - Abigel Sebok-Tornai
AU - Marta Wilhelm
AU - Krisztian Kvell
PY - 2026
DA - 2026/07/29
JO - Cancer Cell International
DO - 10.1186/s12935-026-04429-6
UR - https://doi.org/10.1186/s12935-026-04429-6
AB - Background: Although regular physical activity is known to reduce cancer risk, the circulating molecular mechanisms responsible for these effects remain incompletely defined. Exercise alters the release and composition of extracellular vesicles (EVs), suggesting a role in systemic anti-tumor signaling. However, the contribution of large EVs (L-EVs) ─ a distinct and understudied EV subtype ─ to the regulation of lung adenocarcinoma cell behaviour has not been examined to date. Methods: L-EVs were isolated from platelet-free plasma of healthy, regularly exercising older adults with over 25 years of training history (aged 61 ± 2 years), collected at rest (Pre) and after (Post) an acute endurance exercise bout. EV fractions were characterized via transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and antibody-based profiling. PC9 lung adenocarcinoma cells were incubated with plasma-derived L-EV–enriched fractions for 24 h. Cell viability and metabolic activity were evaluated using ATP-based luminescence and XTT assays following L-EV treatment. miRNA and gene expression changes were assessed using RT-qPCR with TaqMan arrays. Differentially expressed miRNAs (DEmiRs) and genes (DEGs) were analysed using Ingenuity Pathway Analysis (IPA) to evaluate regulatory networks and predict functional outcomes. Results: Exercise significantly increased plasma nanoparticle concentration (mean increase of 5.05 × 10⁷ ± 9.99 × 10⁶ particles/mL; p < 0.001, Cohen’s d = 1.685). TEM and NTA confirmed successful isolation of L-EVs, with mode sizes of 136.1 ± 23.6 nm pre-exercise and 129.5 ± 17.7 nm post-exercise. In PC9 cells, both Pre- and Post-L-EVs reduced metabolic activity compared to control conditions, as demonstrated by ATP-based and XTT assays, indicating a functional impact on cell viability (p < 0.001). Transcriptomic analysis revealed distinct expression changes between conditions. Post-L-EVs downregulated oncogenic and immune evasion–associated genes (MAX, FASLG, and ELK1) while upregulating pro-apoptotic and cell cycle inhibitory genes (CASP9, FADD, and CDKN2B). Several DEmiRs, including miR-21-5p, miR-301b-3p, and miR-193a-3p, shifted in directions opposite to their known oncogenic patterns in NSCLC, suggesting a tumor-suppressive influence. IPA predicted enhanced apoptotic signaling and reduced metastatic potential following Post-L-EV treatment. Conclusion: Exercise-conditioned plasma-derived enriched L-EVs modulate gene and miRNA expression in lung adenocarcinoma cells toward a tumor-suppressive profile. By attenuating oncogenic and immune-evasion signals while enhancing apoptotic and cell cycle–inhibitory pathways, Post-L-EVs offer preliminary mechanistic insight into the anti-cancer potential of physical activity. Their origin from older adults engaged in long-term exercise highlights the systemic benefits of sustained activity and the promise of L-EVs as biomarkers of exercise responsiveness. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12935-026-04429-6.
SN - 1475-2867
ER -